Adc Therapeutics Sa Stock Fundamentals
| ADCT Stock | USD 1.85 0.08 4.52% |
ADC Therapeutics SA fundamentals help investors to digest information that contributes to ADC Therapeutics' financial success or failures. It also enables traders to predict the movement of ADC Stock. The fundamental analysis module provides a way to measure ADC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADC Therapeutics stock.
At this time, ADC Therapeutics' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 57.9 M in 2025, whereas Interest Income is likely to drop slightly above 5 M in 2025. ADC | Select Account or Indicator |
ADC Therapeutics SA Company Current Valuation Analysis
ADC Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ADC Therapeutics Current Valuation | 21.42 M |
Most of ADC Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ADC Therapeutics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ADC Therapeutics SA has a Current Valuation of 21.42 M. This is 99.85% lower than that of the Communications Equipment sector and 99.54% lower than that of the Information Technology industry. The current valuation for all United States stocks is 99.87% higher than that of the company.
ADC Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ADC Therapeutics's current stock value. Our valuation model uses many indicators to compare ADC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ADC Therapeutics competition to find correlations between indicators driving ADC Therapeutics's intrinsic value. More Info.ADC Therapeutics SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, ADC Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ADC Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ADC Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADC Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics of similar companies.ADC Therapeutics is currently under evaluation in current valuation category among its peers.
ADC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 2.1B | 1.6B | 300.1M | 135.6M | 156.0M | 148.2M | |
| Enterprise Value | 1.7B | 1.2B | 91.0M | (18.6M) | (21.4M) | (20.3M) |
ADC Fundamentals
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (3.00) % | ||||
| Operating Margin | (1.93) % | ||||
| Current Valuation | 21.42 M | ||||
| Shares Outstanding | 96.69 M | ||||
| Shares Owned By Insiders | 20.64 % | ||||
| Shares Owned By Institutions | 63.17 % | ||||
| Number Of Shares Shorted | 5.3 M | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 2.53 X | ||||
| Revenue | 69.56 M | ||||
| Gross Profit | (59.85 M) | ||||
| EBITDA | (146.76 M) | ||||
| Net Income | (240.05 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 124.38 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (1.78) X | ||||
| Cash Flow From Operations | (118.69 M) | ||||
| Short Ratio | 11.50 X | ||||
| Earnings Per Share | (2.39) X | ||||
| Price To Earnings To Growth | 0.74 X | ||||
| Target Price | 8.8 | ||||
| Number Of Employees | 273 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 178.88 M | ||||
| Total Asset | 354.78 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 268.62 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
| Net Asset | 354.78 M |
About ADC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.3 M | 4.5 M | |
| Total Revenue | 80 M | 50.1 M | |
| Cost Of Revenue | 2.3 M | 2.2 M | |
| Stock Based Compensation To Revenue | 0.22 | 0.21 | |
| Sales General And Administrative To Revenue | 0.80 | 0.76 | |
| Research And Ddevelopement To Revenue | 2.10 | 2.00 | |
| Capex To Revenue | 0.05 | 0.05 | |
| Revenue Per Share | 0.77 | 0.54 | |
| Ebit Per Revenue | (2.15) | (2.26) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.